Skip to main content

Table 3 Anti-hypertensive (anti-HTN) drugs distribution

From: Relationship of autonomic imbalance and circadian disruption with obesity and type 2 diabetes in resistant hypertensive patients

Characteristic/Variable Non-T2D group (n = 15) T2D group (n = 10) p-value
Total anti-HTN drugs* 3.3 ± 0.5 [3.1 - 3.6] 4.1 ± 0.7 [3.6 - 4.6] 0.02
Thiazide diuretic 100% (15) 100% (10) -
Aldosterone receptor inhibitor 26.6% (4) 50% (5) 0.40
Angiotensin converting enzyme inhibitor 66.6% (10) 50% (5) 0.68
Angiotensin receptor blocker 40% (6) 70% (7) 0.23
Calcium channel blocker 86.6% (13) 100% (10) 0.50
Centrally acting anti-hypertensive drug 6.6% (1) 40% (4) 0.12
  1. The values are expressed as means ± standard deviation; [95% confidence interval]; (*) Statistical significance (p < 0.05). Non-T2D: non type 2 diabetes resistant hypertension; T2D: type 2 diabetes resistant hypertension.